MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction
On September 9, 2026, MetaVia, Inc. (MTVA) announced preclinical results providing mechanistic support for the waist circumference reduction...
95 Views
MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726
On August 6, 2026, MetaVia, Inc. (MTVA) announced financial results for the second quarter of 2026 and provided a business update. The company...
99 Views
Primer: MetaVia (MTVA US) - Aug 2026
MetaVia is a clinical-stage biotechnology company focused on the high-growth cardiometabolic disease sector, with lead assets targeting obesity...
97 Views
MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions
On June 8, 2026, MetaVia, Inc. (MTVA) announced the presentation of new late-breaking data for DA-1726, the company's oxyntomodulin analog...
113 Views
MTVA: No Evidence for Changes in Cardiovascular Parameters in Phase 1 Trial of DA-1726
On May 27, 2026, MetaVia, Inc. (MTVA) announced the presentation of new Phase 1 data for DA-1726, the company's oxyntomodulin analog targeting...
104 Views